Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases.

Medical Oncology
Faruk TasErkan Topuz

Abstract

In this study we have investigated changes in circulating angiogenic factors after a single zoledronic acid intravenous infusion. Thirty consecutive patients who had histologically confirmed breast (n=20) and lung cancer (n=10) associated with confirmation of bone metastases were included in the study. Serum was also available from 10 healthy volunteers. Four mg of Zoledronic acid (Zometa, Novartis) was administered as a 15-min infusion in 100-ml normal saline on an outpatient basis. Venous blood for assessment of serum parameters was drawn just before the beginning of drug infusion and again at 7 and 28 days after the zoledronic acid infusion. Serum levels of VEGF and bFGF were assayed with ELISA kits. Serum VEGF and bFGF levels were not significantly different from healthy control groups (P>0.05). However, we found that serum VEGF levels in lung cancer patients were significantly higher than in patients with breast cancer and controls (P=0.009, and P=0.022, respectively). We found no significant correlation between serum VEGF and bFGF levels. No statistically significant changes were seen following infusion of zoledronic acid in patients with bone metastases for both serum VEGF and bFGF levels (P>0.05). Unlike previous studie...Continue Reading

Associated Clinical Trials

References

Aug 17, 2002·The Journal of Pharmacology and Experimental Therapeutics·Jeanette WoodJonathan R Green
Jan 28, 2003·Cancer·Jonathan R Green
Feb 4, 2003·American Journal of Clinical Oncology·Jonathan R Green, Philippe Clézardin
Dec 9, 2003·The Breast : Official Journal of the European Society of Mastology·P CroucherR Coleman
Mar 16, 2005·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Bruno VincenziGiuseppe Tonini

❮ Previous
Next ❯

Citations

Dec 19, 2009·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·M H VieillardG Penel
Apr 1, 2010·International Journal of Clinical Oncology·Mohamed S ZaghloulMohamed Nazmy
Dec 15, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Junro YamashitaLaurie K McCauley
Nov 24, 2011·Endocrinology·Shinichiro KuroshimaJunro Yamashita
Nov 3, 2011·Future Oncology·Stephen MetcalfRichard Morgan
Mar 1, 2012·Cancer Treatment Reviews·Nigel Bundred
Jan 3, 2013·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Ana Carolina Uchoa VasconcelosKaren Cherubini
Apr 26, 2014·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·S ZafarG J Seymour
Dec 9, 2015·BoneKEy Reports·Erik F Eriksen
Sep 3, 2010·Nature Reviews. Clinical Oncology·Tomifumi OnishiNaoto T Ueno
Apr 20, 2019·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Erofili PapadopoulouDimitrios Bafaloukos
Jul 3, 2010·Ultrastructural Pathology·I PerrottaM Giudice

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.